Peak Asset Management LLC increased its position in Pfizer Inc. (NYSE:PFE) by 0.4% during the second quarter, Holdings Channel reports. The firm owned 35,484 shares of the biopharmaceutical company’s stock after buying an additional 150 shares during the period. Peak Asset Management LLC’s holdings in Pfizer were worth $1,249,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in the company. Godsey & Gibb Associates boosted its position in Pfizer by 1.4% in the first quarter. Godsey & Gibb Associates now owns 419,019 shares of the biopharmaceutical company’s stock worth $12,420,000 after buying an additional 5,704 shares during the period. Mondrian Investment Partners LTD boosted its position in Pfizer by 5.0% in the first quarter. Mondrian Investment Partners LTD now owns 3,640,834 shares of the biopharmaceutical company’s stock worth $107,914,000 after buying an additional 172,498 shares during the period. Bowling Portfolio Management LLC boosted its position in Pfizer by 137.7% in the first quarter. Bowling Portfolio Management LLC now owns 226,975 shares of the biopharmaceutical company’s stock worth $6,728,000 after buying an additional 131,482 shares during the period. Gagnon Securities LLC bought a new position in Pfizer during the first quarter worth $258,000. Finally, Lakeview Capital Partners LLC boosted its position in Pfizer by 3.1% in the first quarter. Lakeview Capital Partners LLC now owns 81,316 shares of the biopharmaceutical company’s stock worth $2,410,000 after buying an additional 2,466 shares during the period. 69.66% of the stock is owned by institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 1.69% during midday trading on Friday, hitting $31.93. The stock had a trading volume of 28,508,651 shares. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The company has a market cap of $193.68 billion, a P/E ratio of 28.31 and a beta of 0.86. The stock’s 50-day moving average is $33.36 and its 200-day moving average is $34.35.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.56 earnings per share. Equities analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.76%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.
Several research firms recently commented on PFE. Sanford C. Bernstein set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Barclays PLC reiterated an “equal weight” rating and issued a $34.00 target price on shares of Pfizer in a research note on Tuesday, August 2nd. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $37.97 target price for the company. in a research note on Thursday, July 14th. Jefferies Group set a $40.00 target price on Pfizer and gave the company a “buy” rating in a research note on Monday, August 1st. Finally, Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. Pfizer presently has an average rating of “Buy” and a consensus target price of $38.48.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.